Africa: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Africa: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

Statement
UPDATE: Statement to Member States regarding thromboembolic events after vaccination with Janssen COVID-19 vaccine (Johnson & Johnson)
24 April 2021
Recommendations to AU Member States and health authorities
COVID-19 vaccines remain a key tool to prevent severe cases and deaths from COVID-19 infection. As such rapid access to safe and effective vaccines is paramount to the African Union vaccination strategy to achieve control of the pandemic.
The currently available evidence underscores the safety and efficacy of Janssen COVID-19 vaccine, notably in settings with high prevalence of the 501Y.V2 (or B.1.351) SARS CoV2 variant.
The position of Africa CDC is that the benefits of the Janssen COVID-19 vaccine outweigh the risks for people who receive it.
National health care authorities should reinforce vaccine safety monitoring.  Health care providers and clinicians should be informed of the risk of thrombotic thrombocytopenia in order to recognize and properly manage this very rare adverse event. Africa CDC will continue to monitor reports of adverse events following immunization, for all COVID-19 vaccines, including the Janssen COVID-19 vaccine, and will provide further guidance to Member States.